Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:EKH-R vs HCA, THC, EHC: Debt-to-Revenue Comparison
For the Medical Care Facilities subindustry, Ekachai Medical Care PCL's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekachai Medical Care PCL Debt-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ekachai Medical Care PCL's Debt-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ekachai Medical Care PCL's Debt-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data,
the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.
Ekachai Medical Care PCL (BKK:EKH-R) has a Debt-to-Revenue of 0.05 as of Jun. 2026.
Is Ekachai Medical Care PCL's Debt-to-Revenue too high?
Ekachai Medical Care PCL's current Debt-to-Revenue is 0.05. Overall, Ekachai Medical Care PCL has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ekachai Medical Care PCL's Debt-to-Revenue compare to HCA and THC?
Ekachai Medical Care PCL's Debt-to-Revenue of 0.05 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Healthcare Providers & Services company?
A good Debt-to-Revenue depends on the Healthcare Providers & Services industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Ekachai Medical Care PCL's current Debt-to-Revenue is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekachai Medical Care PCL stock overvalued right now?
Based on GuruFocus' analysis, Ekachai Medical Care PCL (BKK:EKH-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿6.17, compared to a current price of ฿5.20 — trading 15.7% below its estimated fair value. The current Debt-to-Revenue is 0.05. Ekachai Medical Care PCL's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Ekachai Medical Care PCL (BKK:EKH-R), the current Debt-to-Revenue is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekachai Medical Care PCL (BKK:EKH-R) Overvalued in 2026?
Based on GuruFocus' analysis, Ekachai Medical Care PCL stock appears to be undervalued.
The current stock price of ฿5.20 is trading 15.7% below its estimated GF Value™ of ฿6.17.
GuruFocus considers Ekachai Medical Care PCL to be Modestly Undervalued.
Key valuation signals for BKK:EKH-R:
Debt-to-Revenue: 0.05
GF Value™: ฿6.17 vs. price of ฿5.20 (15.7% below fair value)
No single metric tells the full story. See the BKK:EKH-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekachai Medical Care PCL is engaged in hospital business. Its services include plastic surgery, IVF Fertility & Genetic Center, Ophthalmology Center, Obstertrics and Gynaecology Center, Pediatrics Center, Orthopedics Center, General Surgery Center, Dental center, therapy, Aesthetic & Dermatology Center, among others. The group is engaged in the hospital business and infertility center. Its operations are carried on only in Thailand.
93GF Score
Get the complete analysis for BKK:EKH-R
Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EKH-R has been successfully added to your 
